|
|
|
| Expression and Immunological Analysis of Recombinant Nesseria Meningitis Group B Recombinant fHBP Fusion Protein |
| PENG Shi-ze, XIAO Hong-jian, PENG Zheng-hua, BI Yan-wei, SUN Zhen-lu, DAI Zong-xiang, GAO Dan-dan, XU Wei-ming LI Zhi-hua, LI Jian-feng |
| Institute of Medical Biology,Chinese Academy of Medical Sciences and Peking Union Medical College,Kunming 650118,China |
|
|
|
Abstract Factor H-binding protein (fHBP) is a novel meningococcal vaccine candidate that elicits serum antibodies that activate classical complement pathway bacteriolysis and also inhibit binding of the complement downregulatory protein, factor H, to the bacterial surface. One limitation of fHBP as a vaccine candidate is antigenic variability, since antibodies to fHBP in the variant 1 (V1) antigenic group do not protect against strains expressing V2 or V3 proteins, and vice versa. It can be defined three domains A,B and C, one epitope expressed by nearly all V1 proteins mapped to the B domain, while epitopes expressed by fHBP V2 or V3 mapped to the C domain. That provided the rationale for engineering chimeric fhbp (which was named fhbp-c2 )molecules containing the full length protein of fHBP V1 and a portion of the C domain protein of fHBP V2 then fhbp-c2 was cloned into the prokaryotic expression vector Pet-30a(+) and expressed in E.coli BL21(DE3).Purified recombinant fHBP-C2 protein stimulated a significant antigen-specific humoral response following two intraperitoneal immunization,while bactericidal assay showed that fHBP-C2 can elicit antibodies capable of inducing bactericidal activity against B N. meningitidis strains.the result indicates that fHBP-C2 is a promising candidate for vaccine development.
|
|
Received: 11 January 2011
Published: 27 May 2011
|
|
|
|
Cite this article:
PENG Shi-ze, XIAO Hong-jian, PENG Zheng-hua, BI Yan-wei, SUN Zhen-lu, DAI Zong-xiang, GAO Dan-dan, XU Wei-ming LI Zhi-hua, LI Jian-feng. Expression and Immunological Analysis of Recombinant Nesseria Meningitis Group B Recombinant fHBP Fusion Protein. China Biotechnology, 2011, 31(5): 28-33.
URL:
https://manu60.magtech.com.cn/biotech/ OR https://manu60.magtech.com.cn/biotech/Y2011/V31/I5/28
|
|
|
|
[1] Perrett K P,Pollard A J.Towards an improved serogroup B Neisseria meningitides.Vaccine,2005,5(12):1611-1625.
[2] Murphy E,Andrew L,Lee K L.Sequence Diversity of the Factor H Binding Protein Vaccine Candidate in Epidemiologically Relevant Strains of Serogroup B Neisseria meningitides.J Infect Dis,2009,200(3):379-389.
[3] Masignani V,Comanducci M,Giuliani M M. Vaccination against Neisseria meningitides Using Three Variants of the Lipoprotein GNA1870. J Exp Med,2003,197(6):789-799.
[4] Brunelli B, Del Tordello E, Palumbo E.Influence of sequence variability on bactericidal activity sera induced by Factor H binding protein variant 1.1. Vaccine,2011,29(5):1072-1081.
[5] Pizza M,Donnelly J,Rappuoli R. Factor H-binding protein, a unique meningococcal vaccine antigen. Vaccine,2008,26 (8): I46-I48.
[6] Beernink P T,Granoff D M. Bactericidal Antibody Responses Induced by Meningococcal Recombinant Chimeric Factor H-Binding Protein .Vaccines,2008,76(6):2568-2575.
[7] Beernink P T,Welsch J A,Bar-Lev M. Fine Antigenic Specificity and Cooperative Bactericidal Activity of Monoclonal Antibodies Directed at the Meningococcal Vaccine Candidate Factor H-Binding Protein. Infect Immun, 2008,76(9):4232-4240.
[8] Frasch C E, Chapman S S. Classification of Neisseria meningitidis group B into distinct serotypes. I. Serological typing by a microbactericidal method. Infect Immun,1972,5(1):98-102.
[9] Giuliani M M,Santini L,Brunelli B,et a1.The region comprising amino acids 100 to 255 of Neisseria meningitides lipoprotein GNA 1870 elicits baetericidal antibodies.Infect Immun,2005,73(2):3762-3771.
[10] Schneider M C,Prosser B E.Neisseria meningitidis recruits factor H using protein mimicry of host carbohydrates. Nature,2009,458(7240): 890-893.
[11] Beernink P T, Shaughnessy J, Ram S.Impaired immunogenicity of a meningococcal factor H-binding protein vaccine engineered to eliminate factor h binding. Clin Vaccine Immunol, 2010,17(7):1074-1078.
[12] Beernink P T, Shaughnessy J, Braga E M. A meningococcal factor h binding protein mutant that eliminates factor h binding enhances protective antibody responses to vaccination. J Immunol, 2011, 186(6):3606-3614.
[13] Dunphy K Y, Beernink P T, Brogioni B.Effect of factor H-binding protein sequence variation on factor H binding and survival of Neisseria meningitidis in human blood. Infect Immun, 2011,79(1):353-359.
[14] Masignani V, Comanducci M, Giuliani M M, et al. Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870. J Exp Med, 2003,197(6):789 -799.
[15] Oriente F,Scarlato V,Delany I. Expression of Factor H Binding Protein of Meningococcus Responds to Oxygen Limitation through a Dedicated FNR-Regulated Promoter. Journal of Bacteriology, 2010, 192(3):691-701.
[16] 陈柳,李健峰,徐维明,等.脑膜炎奈瑟氏菌外膜蛋白NhhA的克隆表达及免疫学分析. 中国生物工程杂志,2010,30(4):8-12. Chen L,Li J F,Xu W M, et al.China Biotechnology, 2010,30(4):8-12.
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
| |
Shared |
|
|
|
|
| |
Discussed |
|
|
|
|
